Your AI-Trained Oncology Knowledge Connection!
Data presented at the Society of Gynecologic Oncology 2021 Annual Meeting on Women’s Cancer found a statistically significant benefit with fuzuloparib maintenance therapy compared with placebo for patients with platinum-sensitive, recurrent ovarian cancer.
HIPEC of paclitaxel and cisplatin during surgical debulking of advanced epithelial ovarian cancer appears to be superior to cisplatin alone, according to findings from a single-institution study.
At the New York GU 14th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Phillip J. Koo, MD, discussed the recommendations issued for the early detection of metastatic prostate cancer using next-generation imaging.
CancerNetwork® spoke with Tzvia Bader about barriers between patients and appropriate clinical trials and how to combat these issues.
In addition to promising effects on tumor progression risk, apatinib added to doxorubicin for ovarian cancer in certain settings increased overall response rate versus single-agent doxorubicin.
GT Biopharma announced updated data focusing on its therapeutic candidate, GTB-3550, to treat certain patients with myelodysplastic syndromes and acute myeloid leukemia.
When compared against nivolumab alone, relatlimab plus nivolumab delayed progression in patients with unresectable stage III and IV untreated melanoma.
The androgen receptor inhibitor enzalutamide, an approved therapy for certain types of prostate cancer, has shown activity for the treatment of patients with recurrent or advanced endometrioid endometrial cancer.
Hardesty detailed her expectations for the focus of the conference and the exciting topical opportunities presented this year’s SGO Annual Meeting compared with past years.
Five-year follow-up data from the SOLO-1 trial continue to show progression-free survival benefit of olaparib as maintenance therapy following platinum-based chemotherapy in the frontline setting for ovarian cancer.
Pyrotinib plus capecitabine to treat patients with HER2-positive metastatic breast cancer saw a statistically significant improvement in progression-free survival.
The Virtual Nodule Clinic artificial intelligence–powered clinical decision support tool was cleared by the FDA for detection of early-stage lung cancer in lung nodules detected by a CT scan.
The phase 3 CheckMate 577 trial is the first to show a checkpoint inhibitor in the adjuvant setting after trimodality therapy demonstrate a statistically significant and clinically meaningful improvement in disease-free survival in patients with resected esophageal and gastroesophageal junction cancer.
Results of prospective, open-label trial of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer continued to demonstrate efficacy of the PARP inhibitor in this setting.
CancerNetwork® sat down with Jeffrey Graham, MD, FRCPC, to discuss the effectiveness of immune checkpoint inhibitors as frontline therapy for non–clear cell renal cell carcinoma
CancerNetwork® discussed updates in the treatment of gynecologic cancers with Ursula A. Matulonis, MD.
Novartis announced that its investigational targeted radioligand therapy 177Lu-PSMA-617 demonstrated statistically significant improvements in overall and radiographic progression-free survival versus standard-of-care therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.
Children, adolescents, and young adult patients in first B-cell acute lymphoblastic leukemia relapse did not experience a statistically significant disease-free survival benefit with blinatumomab treatment compared with chemotherapy.
Adjuvant immunotherapy treatment was associated with a significant survival benefit for patients with stage II melanoma in a study presented at the Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care.
Based on positive overall and progression-free survival data from the phase 3 KEYNOTE-590 trial, pembrolizumab was approved by the FDA for use in patients with metastatic or locally advanced esophageal or gastroesophageal junction carcinoma.
In a phase 1 trial, the recommended phase 2 dose of glofitamab resulted in frequent and durable complete responses for patients with follicular lymphoma and transformed diffuse large B-cell lymphoma arising from follicular lymphoma.
Take a look back at some of the important news and notes from last week in the world of oncology, featuring news about breast cancer, prostate cancer, molecular profiling, ovarian cancer, and more.
The combination of cediranib and olaparib demonstrated modest efficacy in patients with recurrent, metastatic, or persistent endometrial cancer; however, this was not significantly different compared to cediranib alone.
Results of the phase 3 IMpower010 trial have demonstrated that adjuvant atezolizumab for patients with stage IB to IIIA non–small cell lung cancer leads to increased disease-free survival versus best supportive care for patients with high PD-L1.
PFS improvement as well as a trend to overall survival prolongation has been demonstrated with niraparib maintenance in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations.
Although responses were limited in patients with paclitaxel-pretreated cervical cancer, eribulin may still show promise in those who are naïve to treatment with the chemotherapy agent.
Data from the phase 2 OVARIO study showed extended progression-free survival benefit of niraparib plus bevacizumab in patients with heavily pretreated advanced ovarian cancer.
A dostarlimab triplet combination showed promise in a phase 2 study for treatment of patients with platinum-resistant ovarian cancer, according to a presentation at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer.
An update from the phase 3 ARIEL4 trial presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer supports the continued use of rucaparib in patients with BRCA-mutant relapsed advanced ovarian cancer, based on progression-free survival and response data.
Patients with newly diagnosed ovarian cancer who had interval debulking surgery and visible residual disease showed promising outcomes when treated with the PARP inhibitor niraparib, according to a post hoc analysis of a phase 3 clinical trial.
